Industry involvement

Professor Velkov has an extensive track record of industry engagement and experience. He has an exceptional record in developing productive collaborations across industry and universities through connections with researchers and pharmaceutical industry leaders (e.g., Qpex & Sliabx). A/Prof Velkov has spent valuable time in industry placements at CSL and Qpex, during his two successive NHMRC CDF 1 and 2 industry fellowships (1009876, 1064896) and a will undertake a MPTConnect REDI Industry Fellowship with Qpex (SanDiego, USA) in 2023.

Key industry partners: Qpex, Silabx, Brii Biosciences, CSL.

Donate to our lab

Whether you want to research, invest, donate or partner with us to accelerate our life-changing discoveries, we'd be delighted to hear from you. We have opportunities for PhD students, post docs and senior researchers to join our lab. Find out more about our lab below. Feel free to contact Professor Tony Velkov with any queries.

Selected funding groups

US National Institute of Health (National Institute for Allergy and Infectious Diseases) 2022 to 2026. US$3.2M Development of a broad spectrum teixobactin-lipopeptide hybrid for the treatment of lung infections caused by pan-drug resistant ‘superbugs’

REDI Industry Fellowship 2023 –2024 Novel lipopeptide antibiotics targeting extremely drug resistant „superbugs“

Department of Defence Congressionally Directed Medical Research Programs. 2020 to 2023
Novel Antimicrobial Hybrid Hydrogel Dressing Targeting Wound Infections Caused by Superbugs Resistant to All Current Antibiotics

Australian Research Council. 2020 to 2023. $394,566.  Antibacterial Material Design via Mechanism-Based Mathematical Modelling

US National Institute of Health (National Institute for Allergy and Infectious Diseases) 2020 to 2024. US$4.9M. Pharmacology of intrathecal/intraventricular polymyxins: A systems-based approach.